- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05175963
Surveillance Among Healthcare Workers for SARS-Coronavirus-2 Infection
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studiecontact
- Naam: Marta Nunes, PhD
- Telefoonnummer: +27 11 983 4283
- E-mail: marta.nunes@wits-vida.org
Studie Contact Back-up
- Naam: Gcinile Gule
- Telefoonnummer: +27 11 983 4283
- E-mail: gcinile.gule@wits-vida.org
Studie Locaties
-
-
GP
-
Johannesburg, GP, Zuid-Afrika, 2192
- Werving
- Chris Hani Baragwanath Academic hospital
-
Contact:
- Marta Nunes, PhD
- Telefoonnummer: +27 11 983 4283
- E-mail: marta.nunes@wits-vida.org
-
Contact:
- Colin Menezes, PhD
- Telefoonnummer: +27 11 983 4283
- E-mail: Colin.Menezes@wits.ac.za
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- HCWs of any staff category at the study hospitals.
Exclusion Criteria:
- None
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: Cohort
- Tijdsperspectieven: Prospectief
Cohorten en interventies
Groep / Cohort |
---|
High Risk
Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in: Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the "pneumonia-admission" ward (ward 24), and staff in the COVID-19 confirmed case wards. Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated "pneumonia ward" and COVID-19 cases wards. Intensive Care Unit: All medical staff working in the intensive care unit. |
Low Risk
Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
|
Intermediate Risk
A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are: VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA. Nurses and medical doctors from the Obstetrics & Gynaecology. |
Mixed Risk
In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
|
TND group
Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To determine the prevalence of symptomatic and asymptomatic SARS-CoV-2 infections among HCW.
Tijdsspanne: 2020
|
To determine the prevalence of symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infections among HCW using a systematic sampling strategy, coupled with investigation when clinically indicated.
|
2020
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
To define the duration of viral "shedding".
Tijdsspanne: 2020
|
To define the duration of "shedding" (using molecular based PCR methods) of SARS-CoV-2 in HCW who are identified to be infected with the virus.
|
2020
|
To do sero-epidemiology assessment.
Tijdsspanne: 2022
|
To undertake serial sero-epidemiology studies on prevalence of SARS-CoV-2 antibodies among HCW.
|
2022
|
To analyse immune responses to SARS-CoV-2 infection.
Tijdsspanne: 2022
|
To analyse immune responses (humoral and cell mediated) to SARS-CoV-2 infection.
|
2022
|
To investigate the possibility of viral re-infection in this population during the study period.
Tijdsspanne: 2022
|
To investigate the possibility of viral re-infection during the different pandemic waves in this population during the study period.
|
2022
|
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity
Tijdsspanne: 2022
|
To establish if common cold coronaviruses (CCCV) immunity confers protection against SARS-CoV-2 infection or disease severity by measuring antibodies to CCCV.
|
2022
|
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.
Tijdsspanne: 2022
|
To evaluate COVID-19 vaccine effectiveness (VE) amongst HCWs, against any PCR-confirmed SARS-CoV-2 infection.
|
2022
|
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.
Tijdsspanne: 2022
|
To measure humoral and cell mediated immune responses to COVID-19 vaccines stratified by previous SARS-CoV-2 infection.
|
2022
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 200405
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...VoltooidPost acute gevolgen van COVID-19 | Post COVID-19-conditie | Lang-COVID | Chronisch COVID-19-syndroomItalië
-
Yang I. PachankisActief, niet wervendCOVID-19 luchtweginfectie | COVID-19 Stresssyndroom | COVID-19 Vaccin Bijwerking | COVID-19-geassocieerde trombo-embolie | COVID-19 post-intensive care-syndroom | COVID-19-geassocieerde beroerteChina
-
Massachusetts General HospitalWervingPost-acuut COVID-19-syndroom | Lange COVID | Post acute gevolgen van COVID-19 | Lange COVID-19Verenigde Staten
-
Indonesia UniversityWervingPost-COVID-19-syndroom | Lange COVID | Post COVID-19-conditie | Post-COVID-syndroom | Lange COVID-19Indonesië
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaWervingCOVID-19 Longontsteking | COVID-19 luchtweginfectie | Covid-19-pandemie | COVID-19 acuut ademnoodsyndroom | COVID-19-geassocieerde longontsteking | COVID 19 geassocieerde coagulopathie | COVID-19 (Coronavirusziekte 2019) | COVID-19-geassocieerde trombo-embolieGriekenland
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaWervingCovid-19-pandemie | Covid-19-vaccins | COVID-19-virusziekteIndonesië
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNog niet aan het wervenPost-COVID-19-syndroom | Lange COVID | Lange Covid19 | Post COVID-19-conditie | Post-COVID-syndroom | Post COVID-19-conditie, niet gespecificeerd | Post-COVID-toestandNederland
-
Sheba Medical CenterOnbekend
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... en andere medewerkersWervingCOVID-19 | Post-COVID-19-syndroom | Postacute COVID-19 | Acuut COVID-19China
-
Endourage, LLCWervingLange COVID | Lange Covid19 | Postacute COVID-19 | Langeafstands COVID | Langeafstands COVID-19 | Postacuut COVID-19-syndroomVerenigde Staten